Pulmonx: Business Model, SWOT Analysis, and Competitors 2026

Pulmonx Corporation stands as a leading company in Healthcare. Generating $90.50 million in annual revenue (growing -4.9% year-over-year) and carrying a market capitalization of $66.41 million, the company has cemented its position as a foundational player in the global Medical Devices landscape. Under the leadership of its leadership team, Pulmonx Corporation continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Pulmonx Corporation's business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Pulmonx Corporation as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Pulmonx Corporation's position in the Medical Devices market today.

What You Will Learn

1. How Pulmonx Corporation generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Pulmonx Corporation's competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Pulmonx Corporation's main competitors are and how the company compares on key financial metrics
4. Pulmonx Corporation's key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Pulmonx Corporation's strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $90.50 million annual revenue (TTM), +-4.9% YoY
• Market Cap: $66.41 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 74.2%, operating margin -43.8%, net margin -59.7%
• Free Cash Flow: Data available in latest quarterly filing
• Return on Equity: -77.2% — reflects current investment phase
• Employees: See latest annual report

Who Owns Pulmonx Corporation?

Pulmonx Corporation is publicly traded on the NMS under the ticker symbol LUNG. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Pulmonx Corporation are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Pulmonx Corporation has approximately 0.04 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $1.61 per share as of early 2026.

Pulmonx Corporation's Mission Statement

Pulmonx Corporation's strategic mission is aligned with its core business activities in the Medical Devices sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Pulmonx Corporation's most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Pulmonx Corporation, the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Pulmonx Corporation's strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Pulmonx Corporation Make Money?

As of 2026, Pulmonx Corporation generates $90.50 million in annual revenue (growing -4.9% year-over-year), with a 74.2% gross margin and -43.8% operating margin. Market capitalization stands at $66.41 million. Here is how the company generates its revenue:

Overview

Pulmonx Corp operates in the medical device industry, focusing on the development of innovative technologies for the treatment of lung diseases. The company’s flagship product, the Zephyr Endobronchial Valve, is a minimally invasive solution designed to treat patients with severe emphysema. The valve works by reducing hyperinflation of the lungs, allowing for improved airflow and better lung function.

Revenue Streams

Pulmonx generates revenue primarily through the sale of its medical devices and systems. This includes:

1. Direct Sales: The majority of Pulmonx's revenue comes from the direct sale of the Zephyr Valve to hospitals and healthcare providers.
2. Leasing and Rental Models: Some hospitals may opt for leasing the technology rather than outright purchasing it, providing an alternative revenue stream.
3. Training and Support Services: Pulmonx offers extensive training and support to healthcare professionals, which can also be monetized as part of the service offering.
4. Clinical Trials and Partnerships: Collaborations with research institutions and clinical trials can provide additional funding and enhance the company’s credibility in the market.

Target Markets

Pulmonx primarily targets healthcare institutions such as hospitals and specialized clinics that treat patients with respiratory conditions. The company’s focus is on regions with high prevalence rates of COPD and emphysema, including North America, Europe, and parts of Asia. Moreover, Pulmonx aims to expand its reach into emerging markets where the burden of respiratory diseases continues to rise.

Value Proposition

Pulmonx's value proposition lies in its commitment to improving patient outcomes through innovative technology. By offering minimally invasive treatments that can significantly enhance lung function, the company not only improves the quality of life for patients but also reduces healthcare costs associated with more invasive procedures and prolonged hospital stays. The integration of robust patient support programs further solidifies Pulmonx’s value in the eyes of healthcare providers.

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review Pulmonx Corporation's latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

Pulmonx Corporation Business Model Canvas

The Business Model Canvas framework provides a structured view of how Pulmonx Corporation creates, delivers, and captures value.

Key Partners: Pulmonx Corporation's key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Medical Devices sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Pulmonx Corporation's most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Pulmonx Corporation's critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (N/A employees), proprietary technology, and financial resources ($69.75M in cash).

Value Propositions: Pulmonx Corporation delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Medical Devices market.

Customer Relationships: Pulmonx Corporation maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Pulmonx Corporation reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Pulmonx Corporation serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Pulmonx Corporation's major costs include cost of goods sold (25.8% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 143.8% of revenue.

Revenue Streams: Pulmonx Corporation generates revenue through its core product and service offerings.

Pulmonx Corporation Competitors

Pulmonx Corporation competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Medical Devices segment of the Healthcare sector.

Pulmonx Corporation SWOT Analysis

A SWOT analysis examines Pulmonx Corporation's internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Pulmonx Corporation's gross margin of 74.2% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -43.8% demonstrates disciplined cost management even at scale.

Weaknesses

• High Financial Leverage: With a debt-to-equity ratio of 104.2, Pulmonx Corporation carries significant debt relative to equity. While manageable given its cash flow, elevated leverage limits financial flexibility and increases vulnerability to rising interest rates.
• Revenue Decline: Year-over-year revenue declined 4.9%, raising questions about demand for Pulmonx Corporation's core offerings and requiring management to articulate a credible recovery path.

Opportunities

• Total Addressable Market: Pulmonx Corporation operates in the Medical Devices segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Pulmonx Corporation's products and services.
• Strategic Acquisitions: With $69.75M in cash and strong free cash flow generation, Pulmonx Corporation is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Pulmonx Corporation's revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Pulmonx Corporation's business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Pulmonx Corporation enters 2026 as a leading company in Healthcare, backed by $90.50 million in annual revenue and a -59.7% net profit margin. The company's 74.2% gross margins and N/A in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Pulmonx Corporation's core markets.

For investors and analysts, Pulmonx Corporation represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Pulmonx, SEC EDGAR – Pulmonx Filings, and Pulmonx's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What is Pulmonx Corp known for?

Pulmonx Corporation generated $90.50 million in annual revenue with a -59.7% net profit margin as of the latest reporting period. The company operates in the Medical Devices sector. For the most current information, consult Pulmonx Corporation's investor relations page.

2. What is the business model of Pulmonx?

Pulmonx Corporation generates $90.50 million in annual revenue (TTM) with a 74.2% gross margin, growing -4.9% year-over-year. The company's revenue model is described in detail in the business model section above.

3. Who are Pulmonx's main competitors?

Pulmonx Corporation competes in the Medical Devices segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Medical Devices center on product differentiation, pricing strategy, and distribution scale.

4. What are the strengths of Pulmonx?

Pulmonx Corporation's core strengths include: Pulmonx Corporation's gross margin of 74.2% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -43.8% demonstrates These advantages contribute to the company's durable competitive position in the Medical Devices sector.

5. What challenges does Pulmonx face?

Pulmonx Corporation faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Pulmonx Corporation's revenue is not fully insulated from macroeconomic cycles, and a recess Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Pulmonx Corporation Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.

6. How is the market for pulmonary care evolving?

Pulmonx Corporation generated $90.50 million in annual revenue with a -59.7% net profit margin as of the latest reporting period. The company operates in the Medical Devices sector. For the most current information, consult Pulmonx Corporation's investor relations page.

7. What opportunities exist for Pulmonx in the future?

Pulmonx Corporation's key growth opportunities include: Pulmonx Corporation operates in the Medical Devices segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environm Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Pulmonx With $69.75M in cash and strong free cash flow generation, Pulmonx Corporation is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.